MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
This notice is given by Imagion Biosystems Limited (the ‘Company’ or ‘IBX’) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (‘Corporations Act’) as modified
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company), a company dedicated to improving healthcare through the early detection of cancer, today advises that it
Highlights: Shareholder entitlement offer seeking to raise up to $2.4 million Funding facility of up to $15 million secured with Mercer Street Global Opportunity Fund,
Highlights: Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Imagion Biosystems has released its Annual Report for the year ending 31 December 2022. [See linked documents below] 2022 Research & Development Highlights: March 2022
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance